Obesity, Morbid
Conditions
Keywords
Obesity, Bariatric surgery, One anastomosis gastric bypass, FundoRingOAGB, Fundoplication
Brief summary
Currently, one anastomosis gastric bypass (OAGB) or mini-gastric bypass (MGB) is a common bariatric procedure for treating obesity. Weight gain after surgery is a big problem in bariatric practice. Therefore, adjustable bands and rings are used, for example, "FobiRing". But foreign material can cause complications - the erosion of the stomach wall. For this reason, surgeons avoid the use of various mechanical devices on living tissues. The greatest criticism is of the OAGB for the likelihood of biliary reflux. In case of reflux of bile into the esophagus after surgery, as a rule, a second operation is required with conversion OAGB to the Roux-en-Y method. In addition, along with obesity, gastroesophageal reflux disease (GERD) are steadily increasing world weight and antireflux surgery must be performed simultaneously with bariatric surgery in obese patients. In these cases, most often in bariatric practice, hiatus cruroraphy is performed, and less often fundoplication using the fundus of the excluded part of the stomach. We hypothesize that total fundoplication can not only treat GERD but also significant prevent the return of weight like after a banded gastric bypass and prevent postoperative bile reflux in the esophagus. The aim study is to compare primary outcome as weight loss after total wrapping of the fundus of the gastric excluded part (FundoRing) and non - wrapping (non - banded) standard method of laparoscopic one anastomosis gastric bypass and measure secondary outcome: bile reflux in the esophagus and GERD symptoms. Methods: Adult participants (n=1000) are randomly allocated to one of two groups: Experimental surgical bariatric procedure in the first (A) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and suture cruroplasty if present hiatal hernia (FundoRingOAGB group); Active comparator surgical bariatric procedure in the second (B) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass and with only suture cruroplasty if present hiatal hernia (OAGB group).
Detailed description
One anastomosis Gastric Bypass/Mini Gastric Bypass (OAGB/MGB) is gaining popularity as a primary surgical treatment for morbid obesity. The aim study is to compare primary outcome as weight loss after total wrapping of the fundus of the gastric excluded part (FundoRing) and non - wrapping (non - banded) standard method of laparoscopic one anastomosis gastric bypass and measure secondary outcome: bile reflux in the esophagus and GERD symptoms. Methods: Adult participants (n=1000) are randomly allocated to one of two groups: Experimental surgical bariatric procedure in the first (A) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and suture cruroplasty if present hiatal hernia (FundoRingOAGB group); Active comparator surgical bariatric procedure in the second (B) group: patients (n=500) undergo the laparoscopic one anastomosis gastric bypass and with only suture cruroplasty if present hiatal hernia (OAGB group). All patients are then followed up 12, 24, 36 months after surgery where record the changing body mass index and and measure secondary outcome: bile reflux in the esophagus and GERD symptoms.
Interventions
laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part and with suture cruroplasty if present hiatal hernia
laparoscopic one anastomosis gastric bypass with suture cruroplasty if present hiatal hernia
Sponsors
Study design
Eligibility
Inclusion criteria
* BMI from 30 to 50 kg / m2. * The person is generally fit for anesthesia (ASA grading 1-2) and surgery. * The person commits to the need for long-term follow-up.
Exclusion criteria
* BMI less than 30 kg / m2 and more than 50 kg / m2. * Prosthetic (mesh) Hiatal herniorrhaphy or large hiatal hernia; * Esophageal shortening * Los Angeles Classification of Oesophagitis (LA grade) C or D reflux esophagitis * History of surgery on the stomach or esophagus * Less than 18 or more than 60 years of age * Not fit for bariatric surgery * Psychiatric illness * Patients unwilling or unable to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of body mass index | Baseline, at 12, 24, 36 months after surgery | The measure is assessing a change of body mass index (kg/m2) in groups . Weight (kg) and height (cm) will be combined with the report of measurement by body mass index (BMI) kg/m2. |
| Number of participants with bile reflux in esophagus | at 12, 24, 36 months after surgery | Endoscopic assessment of bile reflux in esophagus and 24-hour pH-impedance monitoring to detect number of postoperative esophageal bile reflux (non-acid reflux) in in each group |
| Number of participants with GERD symptoms | Baseline, 12, 24, 36 months after surgery | Change of GERD symptoms (use GERD Health-related Quality of Life (GERD-HRQL) Questionnaire) if present GERD or number of participants with postoperative de Novo GERD. Scoring Scale 0 = No symptoms 1. = Symptoms noticeable but not bothersome 2. = Symptoms noticeable and bothersome but not every day 3. = Symptoms bothersome every day 4. = Symptoms affect daily activities 5. = Symptoms are incapacitating - unable to do daily activities |
| Frequency of late (>30 day) postoperative complication in each groups | >30 days, at 12, 24, 36 months after surgery | Namber participants with late postoperative complication ( dumping syndrome, marginal ulcer, food intolerance, protein malnutrition, anemia, thiamine deficiency) |
| Chance of the components of Metabolic Syndrome (MetS) after surgery | baseline, 1 and 3-year follow-up | Chance of level of HbA1c (\<5,7%), level of HOMA-IR (\<2.7) , \< number participants with type 2 diabetes and arterial hypertension and chanqe of Lipid profile (Total Cholesterol: \<200 mg/dL, LDL Cholesterol: \<100 mg/dL (optimal), HDL Cholesterol: \>60 mg/dL (desirable), Triglycerides: \<150 mg/dL) at 1 and 3-year follow-up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Oral glucose tolerance tests | Blood samples for glucose collects at 0, 15, 30, 60, 120, 150 and 180 minutes, while those for insulin collects at 0, 30, 60, 120 and 180 minutes | A standard 3-hour oral glucose tolerance tests performs using 75 g glucose |
| Sigstad score | 6, 12, 24, 36 months after surgery | Sigstad score for questionnaire of diagnostic the dumping syndrome. The Sigstad score is a diagnostic index for dumping syndrome, with a score \>7 indicating a high probability of the condition, while a score \< 4 suggests alternative diagnoses. Key Elements of the Sigstad Scoring System: * Thresholds: \< or =3 (Negative), 4-7 (Doubtful), \>7 (Positive for dumping). * Key Symptoms Evaluated: Shock (+5), almost fainting/syncope (+4), desire to lie/sit down (+4), sweating/pallor (+4), palpitations (+2), nausea, and abdominal fullness. |
Countries
Kazakhstan
Contacts
President of Society of Bariatric and Metabolic Surgeons of Kazakhstan" (SBMSK)